BRUCE M EWENSTEIN, M.D.
Osteopathic Medicine at Claflin Path, Brookline, MA
License number
Massachusetts 52653
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
15 Claflin Path, Brookline, MA 02445
Phone
(617) 731-9211
Personal information
See more information about BRUCE M EWENSTEIN at radaris.comName
Address
Phone
15 Claflin Path #1, Brookline, MA 02445
15 Claflin Path, Brookline, MA 02445
Brookline, MA
15 Claflin Path, Brookline, MA 02445
15 Claflin Pl, Newtonville, MA 02460
Professional information
Dr. Bruce M Ewenstein, Brookline MA - MD (Doctor of Medicine)
Specialties:
Hematology
Address:
15 Claflin Path, Brookline 02445
(617) 731-9211 (Phone)
(617) 731-9211 (Phone)
Certifications:
Hematology, 1986, Internal Medicine, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
15 Claflin Path, Brookline 02445
Brigham and Women's Hospital
75 Francis St, Boston 02115
Brigham and Women's Hospital
75 Francis St, Boston 02115
Education:
Medical School
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1980
Bronx Muni Hosp Ctr
Brigham and Womens Hospital
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1980
Bronx Muni Hosp Ctr
Brigham and Womens Hospital
Treatment Of Coagulation Disease By Administration Of Recombinant Vwf
US Patent:
2012031, Dec 13, 2012
Filed:
Jun 11, 2012
Appl. No.:
13/493926
Inventors:
Friedrich Scheiflinger - Vienna, AT
Peter Turecek - Klosterneuburg, AT
Bruce Ewenstein - Brookline MA, US
Wing Yen Wong - Simi Valley CA, US
Tobias M. Suiter - Vienna, AT
Peter Turecek - Klosterneuburg, AT
Bruce Ewenstein - Brookline MA, US
Wing Yen Wong - Simi Valley CA, US
Tobias M. Suiter - Vienna, AT
Assignee:
Baxter Healthcare S.A. - Glattpark (Opfikon)
Baxter International Inc. - Deerfield IL
Baxter International Inc. - Deerfield IL
International Classification:
A61K 38/36, A61P 7/04, A61K 38/37
US Classification:
514 141, 514 137
Abstract:
The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII.